Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05617040
• Other study ID #: PCA001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 30, 2023
• Est. completion date: April 2027

Study information

• Verified date: October 2023
• Source: Vaccitech (UK) Limited
• Contact: General enquiries
• Phone: (+44) 1865 818 808
• Email: enquiries[@]vaccitech.co.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.

Description:

This is a multi-center Phase 1/2 clinical trial to evaluate safety, PSA response, and immunogenicity of the VTP850 prime-boost immunotherapeutic in men with biochemical recurrence of prostate cancer (PCa) after definitive local therapy for PCa. VTP-850 consists of 2 components: ChAdOx1-PCAQ and MVA-PCAQ. All participants will receive ChAdOx1-PCAQ on Day 1 (prime) and MVA-PCAQ on Days 29 and 57 (boosts; Intervention Period). Participants will be followed for 6 months or until start of new therapy such as Androgen Deprivation Therapy (ADT) or until development of unequivocal metastatic PCa (Short-term Follow-up Period). Participants who have a prostate-specific antigen (PSA) response, defined as ≥50% reduction in serum PSA compared to baseline at any time, measured twice consecutively, at least 2 weeks apart, during the 6 months follow up will be followed for an additional 18 months, up to 24 months from first dose, or until start of new therapy such as ADT or development of unequivocal metastatic PCa (Long-term Follow-up Period). Phase 1 (15-18 participants) will follow a 3+3 design to determine the recommended phase 2 regimen (RP2R; dose level of both ChAdOx1-PCAQ and MVA-PCAQ, and route of administration of MVA-PCAQ (IM or IV)) that will be used in Phase 2. Phase 2 will consist of 2 sequential stages. In Stage 1 of Phase 2, 19 additional participants will be enrolled at the chosen Phase 2 regimen. If 4 or more of the 25 participants at the RP2R (including the Phase 1 participants who received the same dose regimen) have a PSA response, Stage 2 will be opened to enrolment of up to 100 additional participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 137
• Est. completion date: April 2027
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males aged 18 years and above at the time of signing the informed consent.

2. Histologically or cytologically confirmed adenocarcinoma of the prostate.

3. Has undergone primary therapy for prostate cancer (radical prostatectomy and/or definitive external beam radiation and/or brachytherapy). Salvage external radiation therapy (XRT) following radical prostatectomy >6 months prior to Day 1 is allowed.

4. No further local therapy to prostate and no metastasis-directed therapy for PSA-positron emission tomography (PET) positive lesions planned within 4 months after the first dose of VTP-850.

5. Serum testosterone >75 ng/dL.

6. Nonmetastatic (M0) disease verified by whole body bone scintigraphy and either CT or MRI. An existing PSMA-PET scan showing no metastatic lesions may be used instead to confirm M0 status. Note that a positive PSMA-PET does not exclude the participant if the conventional scans are negative.

7. Serum PSA of >0.3 ng/mL for participants with prior radical prostatectomy (with or without salvage radiotherapy), or serum PSA of 2 ng/mL above nadir for participants with prior external beam radiation or brachytherapy.

8. PSA doubling time =12 months.

9. Not planning to start ADT for at least 4 months after Day 1.

10. Eastern Cooperative Oncology Group (ECOG) Score 0 or 1.

11. Baseline laboratory parameters must meet the following criteria:

• Haemoglobin =110 g/L
• White cell count =2.0×10^9/L
• Absolute neutrophil count =1.5×10^9/L
• Lymphocytes =0.9×10^9/L
• Platelets =100×10^9/L
• Creatinine =1.5×upper limit of normal (ULN) OR calculated creatinine clearance =50 mL/min by the Cockcroft Gault formula
• Total bilirubin =1.5×ULN, (total bilirubin >1.5×ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35%)
• Alanine aminotransferase =1.5×ULN
• Aspartate aminotransferase =1.5×ULN

12. Agrees to the following during the trial for at least 65 days after the last dose of

VTP-850:

• Refrain from donating sperm PLUS, either
• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
• Agrees to use a male condom when having sexual intercourse with a woman of childbearing potential, and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak.

13. Agrees to comply with all scheduled visits, VTP-850 administration plan, laboratory tests, lifestyle considerations and other trial procedures

Exclusion Criteria:

1. Any other prior malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.

2. Unstable medical condition, drug or alcohol abuse, or medical or psychiatric condition that in the opinion of the investigator would affect the safety of the participant or the evaluation of the data or interfere with adherence to the trial requirements.

3. Significant history of or current cardiovascular, respiratory, renal, gastrointestinal, endocrinological, haematological or neurological disorders constituting a risk when taking the trial intervention or interfering with the interpretation of data; cardiac event or heart failure in the previous 6 months.

4. Current or chronic history of liver disease. This includes but is not limited to:

hepatitis virus infections, cirrhosis, drug- or alcohol-related liver disease, non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, a-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis or any other liver disease considered clinically significant by the investigator. (Note that Gilbert's syndrome or non-alcoholic fatty liver not associated with steatohepatitis are not exclusions.)

5. Active autoimmune disease that has required systemic treatment in past 2 years with use of disease modifying agents, chronic corticosteroids (>14 days) or immunosuppressive drugs. Hormone replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed.

6. History of severe allergy to eggs or history of severe reaction to any previous vaccination that required medical attention.

7. Medical history that could increase the participant's risk of reaction to a vaccine, including but not limited to capillary leak syndrome, transverse myelitis, multiple sclerosis, Guillain Barré syndrome, significant thrombocytopenia, thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia), heparin-induced thrombocytopenia, or hereditary angioedema, acquired angioedema or idiopathic angioedema.

8. Any immunocompromised state, or history of solid organ or stem cell transplantation.

9. Active infection requiring parenteral antibiotic therapy or causing fever (temperature =38.0°C) within 7 days prior to Day 1, or unexplained fever (temperature =38.0°C) within 7 days prior to Day 1.

10. Known history of infection with hepatitis B virus, hepatitis C virus or human immunodeficiency virus.

11. Received XRT following radical prostatectomy within 6 months prior to Day 1.

12. Received ADT within 6 months prior to Day 1.

13. Prior chemotherapy or immunotherapy (including vaccines or checkpoint inhibitors) or experimental agent for prostate cancer.

14. Received a vaccine with adenovirus vector within 3 months prior to Day 1.

15. Received any live vaccine within 30 days prior to Day 1, or planned vaccination to occur within 3 months after Day 1.

16. Received any non-live/inactivated vaccine within 14 days of Day 1 or planned non-live vaccination to occur within 10 weeks after Day 1.

17. Administration of immunoglobulins and/or any blood products within 28 days prior to Day 1.

18. Condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days of first dose of VTP-850. Note that adrenal replacement doses are permitted. Inhaled and topical corticosteroids are allowed.

19. Received an investigational product or investigational surgical procedure in the 3 months prior to Day 1 or planned use during the trial period.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms
• Recurrence

Intervention

Biological:
• ChAdOx1-PCAQ
Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
• MVA-PCAQ
Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))

Locations

Country	Name	City	State
United States	University of Virginia Health System	Charlottesville	Virginia
United States	Houston Methodist Urology Associates, Texas Medical Center	Houston	Texas
United States	Carolina Urologic Research Center	Myrtle Beach	South Carolina
United States	Columbia University Irving Medical Center	New York	New York
United States	Nebraska Cancer Specialists	Omaha	Nebraska
United States	XCancer	Omaha	Nebraska
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital	Philadelphia	Pennsylvania
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Fred Hutchinson Cancer Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Vaccitech (UK) Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Immunogenicity response (antigen-specific T cell magnitude, phenotype and functionality associated with each regimen)	CD4+ and CD8+ T cell response to the VTP-850 antigens in peripheral blood	12 months
Other	The association of PSA response with biomarkers	Microsatellite instability-high (MSI-H) status, BReast CAncer gene (BRCA) mutations (and other molecular markers).; Expression level of the VTP-850 antigens in historic tumour samples. Circulating tumour DNA. Serum PSA-binding antibodies. Other immune responses to VTP-850.	12 months
Other	Resolution of lesions on prostate-specific membrane antigen (PSMA) scan after VTP-850, and association with PSA response	Assessed by PMSA scans	6 months
Other	MFS and TTM of all participants	MFS is defined as time from first dose of VTP-850 until metastatic disease by conventional imaging or death from any cause, whichever occurs first. TTM is defined as time from date of first dose of VTP-850 until metastatic disease by conventional imaging.	24 months
Primary	The safety of VTP-850 prime-boost regimens, with the booster dose administered either IM or IV, and the recommended phase 2 regimen (RP2R)	Participants with (treatment-related) AEs, =Grade 3 (treatment-related) AEs, and (treatment-related) serious adverse events.; Participants with clinically significant laboratory values. Change from baseline for laboratory tests and vital signs.	43 days
Secondary	The PSA response rate to VTP-850	Percentage of participants with =50% reduction in serum PSA compared to baseline (2 consecutive measurements)	6 months
Secondary	The durability of PSA response rate to VTP-850	Percentage of participants with =50% reduction in serum PSA at 8 months, compared to baseline	14 months
Secondary	The duration of PSA response to VTP-850	Time from first dose of VTP-850 to PSA progression	24 months
Secondary	The metastasis-free survival (MFS) and time to metastases (TTM) of participants with a PSA response	MFS is defined as time from first dose of VTP-850 until metastatic disease by conventional imaging or death from any cause, whichever occurs first. TTM is defined as time from date of first dose of VTP-850 until metastatic disease by conventional imaging.	24 months
Secondary	The time to start of androgen deprivation therapy (ADT) for participants with a PSA response	Time from first dose of VTP-850 to the start of ADT or the date when criteria to start ADT are met	24 months